261 related articles for article (PubMed ID: 25260362)
21. NTP technical report on the toxicology and carcinogenesis studies of Elmiron (Cas No. 37319-17-8) in F344/N rats and B6C3F1 mice (Gavage Studies).
National Toxicology Program, Public Health Services, National Institutes of Health, US Department of Health and Human Services,
Natl Toxicol Program Tech Rep Ser; 2004 May; (512):7-289. PubMed ID: 15213766
[TBL] [Abstract][Full Text] [Related]
22. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC
Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760
[TBL] [Abstract][Full Text] [Related]
23. Toxicology and Carcinogenesis Studies of Ochratoxin A (CAS No. 303-47-9) in F344/N Rats (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1989 May; 358():1-142. PubMed ID: 12695783
[TBL] [Abstract][Full Text] [Related]
24. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers.
Macha S; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Diabetes Obes Metab; 2013 Apr; 15(4):316-23. PubMed ID: 23094794
[TBL] [Abstract][Full Text] [Related]
25. Sex-, Species-, and Tissue-Specific Metabolism of Empagliflozin in Male Mouse Kidney Forms an Unstable Hemiacetal Metabolite (M466/2) That Degrades to 4-Hydroxycrotonaldehyde, a Reactive and Cytotoxic Species.
Taub ME; Ludwig-Schwellinger E; Ishiguro N; Kishimoto W; Yu H; Wagner K; Tweedie D
Chem Res Toxicol; 2015 Jan; 28(1):103-15. PubMed ID: 25489797
[TBL] [Abstract][Full Text] [Related]
26. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.
Macha S; Koenen R; Sennewald R; Schöne K; Hummel N; Riedmaier S; Woerle HJ; Salsali A; Broedl UC
Clin Ther; 2014 Feb; 36(2):280-90.e1. PubMed ID: 24491572
[TBL] [Abstract][Full Text] [Related]
27. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
Kern M; Klöting N; Mark M; Mayoux E; Klein T; Blüher M
Metabolism; 2016 Feb; 65(2):114-23. PubMed ID: 26773934
[TBL] [Abstract][Full Text] [Related]
28. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
29. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes.
Riggs MM; Staab A; Seman L; MacGregor TR; Bergsma TT; Gastonguay MR; Macha S
J Clin Pharmacol; 2013 Oct; 53(10):1028-38. PubMed ID: 23940010
[TBL] [Abstract][Full Text] [Related]
31. NTP Toxicology and Carcinogenesis Studies of Pyridine (CAS No. 110-86-1) in F344/N Rats, Wistar Rats, and B6C3F1 Mice (Drinking Water Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2000 Mar; 470():1-330. PubMed ID: 12579203
[TBL] [Abstract][Full Text] [Related]
32. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
Oelze M; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Mikhed Y; Stamm P; Mader M; Zinßius E; Agdauletova S; Gottschlich A; Steven S; Schulz E; Bottari SP; Mayoux E; Münzel T; Daiber A
PLoS One; 2014; 9(11):e112394. PubMed ID: 25402275
[TBL] [Abstract][Full Text] [Related]
33. Empagliflozin for the treatment of Type 2 diabetes.
Gangadharan Komala M; Mather A
Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
[TBL] [Abstract][Full Text] [Related]
34. NTP Toxicology and Carcinogenesis Studies of N-Phenyl-2-naphthylamine (CAS No. 135-88-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1988 Jan; 333():1-168. PubMed ID: 12732903
[TBL] [Abstract][Full Text] [Related]
35. NTP Toxicology and Carcinogenesis of 1,2,3-Trichloropropane (CAS No. 96-18-4) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Aug; 384():1-348. PubMed ID: 12692652
[TBL] [Abstract][Full Text] [Related]
36. Alpha 2u-globulin nephropathy and carcinogenicity following exposure to decalin (decahydronaphthalene) in F344/N rats.
Dill JA; Lee KM; Renne RA; Miller RA; Fuciarelli AF; Gideon KM; Chan PC; Burka LT; Roycroft JH
Toxicol Sci; 2003 Apr; 72(2):223-34. PubMed ID: 12660359
[TBL] [Abstract][Full Text] [Related]
37. Toxicology and Carcinogenesis Studies of Mercuric Chloride (CAS No. 7487-94-7) in F344 Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Feb; 408():1-260. PubMed ID: 12621522
[TBL] [Abstract][Full Text] [Related]
38. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
39. Toxicology and carcinogenesis studies of pulegone (CAS No. 89-82-7) in F344/N rats and B6C3F1 mice (gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2011 Aug; (563):1-201. PubMed ID: 21921962
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of empagliflozin, a novel and selective sodium-glucose co-transporter-2 inhibitor, labeled with carbon-14 and carbon-13.
Hrapchak M; Latli B; Wang XJ; Lee H; Campbell S; Song JJ; Senanayake CH
J Labelled Comp Radiopharm; 2014 Oct; 57(12):687-94. PubMed ID: 25332189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]